Background Lumbar puncture (LP) as a procedure has become increasingly relevant for people with Huntington’s disease (HD) both to administer intrathecal investigational medicinal products, such as antisense oligonucleotides and to collect cerebrospinal fluid (CSF) to develop and validate biological markers to track disease stage and progression.
Despite this increased utilization of LP procedures in HD, the literature is still unclear about its safety profile.
Aims We aimed to investigate the safety profile of LP in people with HD.
Methods We conducted a multi-study crossectional survey including eligible participants from the HDClarity (NCT02855476), HD-YAS (Scahill/Zeun et al, 2020), and NHS (NCT03664804; UCL cohort only) studies, collected between February 2016 to January 2020. Eligible participants were healthy controls, premanifest and manifest gene expansion carriers. We investigate the odds of any adverse events, headaches, and back pain independently. Intergroup comparisons and adjusted event odds were derived using hierarchical logistic regressions.
Results A total of 684 LP involving 500 study participants were included in this analysis (139 healthy controls, 179 premanifest HD, 182 manifest HD). The detailed results of our analysis will be presented at the European HD Network meeting.
Conclusions The LP is safe in patients with HD.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.